|Bid||15.560 x 26300|
|Ask||15.870 x 25300|
|Day's Range||15.382 - 15.525|
|52 Week Range||11.708 - 17.960|
|PE Ratio (TTM)||-8.82|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The Albany, New York-based company said it had a loss of 25 cents per share. Earnings, adjusted for one-time gains and costs, came to 13 cents per share. The results beat Wall Street expectations. The ...
Drug manufacturer Albany Molecular Research Inc. is looking at a $1 billion sale, according to Bloomberg News. AMRI is working with Credit Suisse Group AG to explore a sale, Bloomberg reports, citing unidentified sources. Carlyle Group LP and Pamplona Capital Management, two private equity firms with records of investing in pharmaceutical and health care deals, have expressed interest.
Why Spark Therapeutics, Albany Molecular Research, and Concert Pharmaceuticals could be great biotech stocks to buy as spring approaches.